Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

BACKGROUND: Adjuvant trastuzumab (Herceptin) treatment of breast cancer patients significantly improves their clinical outcome. Vaccination is an attractive alternative approach to provide HER-2/neu (Her2)-specific antibodies and may in addition concomitantly stimulate Her2-reactive T-cells. Here we...

Descripción completa

Detalles Bibliográficos
Autores principales: Norell, Håkan, Poschke, Isabel, Charo, Jehad, Wei, Wei Z, Erskine, Courtney, Piechocki, Marie P, Knutson, Keith L, Bergh, Jonas, Lidbrink, Elisabet, Kiessling, Rolf
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903523/
https://www.ncbi.nlm.nih.gov/pubmed/20529245
http://dx.doi.org/10.1186/1479-5876-8-53

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903523/
https://www.ncbi.nlm.nih.gov/pubmed/20529245
http://dx.doi.org/10.1186/1479-5876-8-53

Ejemplares similares